238 related articles for article (PubMed ID: 26112098)
1. The Role of Topical Brimonidine Tartrate Gel as a Novel Therapeutic Option for Persistent Facial Erythema Associated with Rosacea.
Johnson AW; Johnson SM
Dermatol Ther (Heidelb); 2015 Sep; 5(3):171-81. PubMed ID: 26112098
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies.
Fowler J; Jackson M; Moore A; Jarratt M; Jones T; Meadows K; Steinhoff M; Rudisill D; Leoni M
J Drugs Dermatol; 2013 Jun; 12(6):650-6. PubMed ID: 23839181
[TBL] [Abstract][Full Text] [Related]
3. Once-daily topical brimonidine tartrate gel 0·5% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies.
Fowler J; Jarratt M; Moore A; Meadows K; Pollack A; Steinhoff M; Liu Y; Leoni M;
Br J Dermatol; 2012 Mar; 166(3):633-41. PubMed ID: 22050040
[TBL] [Abstract][Full Text] [Related]
4. Paradoxical Erythema Reaction of Long-term Topical Brimonidine Gel for the Treatment of Facial Erythema of Rosacea.
Lowe E; Lim S
J Drugs Dermatol; 2016 Jun; 15(6):763-5. PubMed ID: 27272086
[TBL] [Abstract][Full Text] [Related]
5. The role of brimonidine tartrate gel in the treatment of rosacea.
Jackson JM; Knuckles M; Minni JP; Johnson SM; Belasco KT
Clin Cosmet Investig Dermatol; 2015; 8():529-38. PubMed ID: 26566370
[TBL] [Abstract][Full Text] [Related]
6. Facial Erythema of Rosacea - Aetiology, Different Pathophysiologies and Treatment Options.
Steinhoff M; Schmelz M; Schauber J
Acta Derm Venereol; 2016 Jun; 96(5):579-86. PubMed ID: 26714888
[TBL] [Abstract][Full Text] [Related]
7. Brimonidine gel 0.33% rapidly improves patient-reported outcomes by controlling facial erythema of rosacea: a randomized, double-blind, vehicle-controlled study.
Layton AM; Schaller M; Homey B; Hofmann MA; Bewley AP; Lehmann P; Nohlgård C; Sarwer DB; Kerrouche N; Ma YM
J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2405-10. PubMed ID: 26416154
[TBL] [Abstract][Full Text] [Related]
8. Spotlight on brimonidine topical gel 0.33% for facial erythema of rosacea: safety, efficacy, and patient acceptability.
Anderson MS; Nadkarni A; Cardwell LA; Alinia H; Feldman SR
Patient Prefer Adherence; 2017; 11():1143-1150. PubMed ID: 28740369
[TBL] [Abstract][Full Text] [Related]
9. A case report of combination treatment with potassium-titanyl phosphate laser and brimonidine topical gel in erythematotelangiectatic rosacea.
Hofmann MA; Kokolakis G
J Cosmet Laser Ther; 2017 Aug; 19(4):222-224. PubMed ID: 28139145
[TBL] [Abstract][Full Text] [Related]
10. Dermatological Adverse Events Associated with Topical Brimonidine Gel 0.33% in Subjects with Erythema of Rosacea: A Retrospective Review of Clinical Studies.
Holmes AD; Waite KA; Chen MC; Palaniswamy K; Wiser TH; Draelos ZD; Rafal ES; Werschler WP; Harvey AE
J Clin Aesthet Dermatol; 2015 Aug; 8(8):29-35. PubMed ID: 26345379
[TBL] [Abstract][Full Text] [Related]
11. Topical brimonidine for the management of facial erythema in rosacea: a histological, histometric, and immunohistochemical study.
El-Domyati M; Rezk AF; Nasif G; Abdelhameed SS; Medhat W
Int J Dermatol; 2023 Jul; 62(7):888-894. PubMed ID: 37212604
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study.
Moore A; Kempers S; Murakawa G; Weiss J; Tauscher A; Swinyer L; Liu H; Leoni M
J Drugs Dermatol; 2014 Jan; 13(1):56-61. PubMed ID: 24385120
[TBL] [Abstract][Full Text] [Related]
13. Topical a-Agonist Therapy for Persistent Facial Erythema of Rosacea and the Addition of Oxmetazoline to the Treatment Armamentarium: Where Are We Now?
Del Rosso JQ
J Clin Aesthet Dermatol; 2017 Jul; 10(7):28-32. PubMed ID: 29104721
[TBL] [Abstract][Full Text] [Related]
14. A split face comparative study using a novel triple combination therapy for the treatment of persistent post acne erythema.
Agamia N; El-Nagdy S; El-Ariny A
Dermatol Ther; 2022 Apr; 35(4):e15327. PubMed ID: 35060229
[TBL] [Abstract][Full Text] [Related]
15. Current drug therapies for rosacea: a chronic vascular and inflammatory skin disease.
Feldman SR; Huang WW; Huynh TT
J Manag Care Spec Pharm; 2014 Jun; 20(6):623-9. PubMed ID: 24856600
[TBL] [Abstract][Full Text] [Related]
16. Optimizing the use of topical brimonidine in rosacea management: panel recommendations.
Tanghetti EA; Jackson JM; Belasco KT; Friedrichs A; Hougier F; Johnson SM; Kerdel FA; Palceski D; Hong HC; Hinek A; Cadena MJ
J Drugs Dermatol; 2015 Jan; 14(1):33-40. PubMed ID: 25607906
[TBL] [Abstract][Full Text] [Related]
17. Brimonidine tartrate for the treatment of facial flushing and erythema in rosacea.
Tong LX; Moore AY
Expert Rev Clin Pharmacol; 2014 Sep; 7(5):567-77. PubMed ID: 25091290
[TBL] [Abstract][Full Text] [Related]
18. Optical coherence tomography imaging of erythematotelangiectatic rosacea during treatment with brimonidine topical gel 0.33%: a potential method for treatment outcome assessment.
Urban J; Siripunvarapon AH; Meekings A; Kalowitz A; Markowitz O
J Drugs Dermatol; 2014 Jul; 13(7):821-6. PubMed ID: 25007365
[TBL] [Abstract][Full Text] [Related]
19. Comparative pharmacokinetics and bioavailability of brimonidine following ocular and dermal administration of brimonidine tartrate ophthalmic solution and gel in patients with moderate-to-severe facial erythema associated with rosacea.
Benkali K; Leoni M; Rony F; Bouer R; Fernando A; Graeber M; Wagner N
Br J Dermatol; 2014 Jul; 171(1):162-9. PubMed ID: 24506775
[TBL] [Abstract][Full Text] [Related]
20. Advances in pharmacotherapy for rosacea: what is the current state of the art?
Dall'Oglio F; Nasca MR; Gerbino C; Micali G
Expert Opin Pharmacother; 2022 Nov; 23(16):1845-1854. PubMed ID: 36330970
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
